World’s research funders launch open-access action plan

The heads of some 70 research funding agencies from around the world said today that they had agreed to encourage open access to science publications resulting from their spending.

But the funders, gathering in Berlin for the second annual meeting of the Global Research Council, a voluntary but potentially influential discussion forum, did not commit to  joint specifics in their seven-page action plan.

Instead, “working out individual details must remain a task for individual organizations”, Peter Strohschneider, the president of Germany’s main research-funding agency, the DFG, told reporters at a press conference. The same broad agreement without detailed how-to recipes applies to another agreement the council released today, a one-page statement on principles for research integrity.

Behind the scenes, “there’s a growing sense of how complex the matter actually is,” Helga Nowotny, the president of the European Research Council, told Nature after the press conference.

Continue reading

Scientists join journal editors to fight impact-factor abuse

If enough eminent people stand together to condemn a controversial practice, will that make it stop?

That’s what more than 150 scientists and 75 science organizations are hoping for today, with a joint statement called the San Francisco Declaration on Research Assessment (DORA). It deplores the way some metrics — especially the notorious Journal Impact Factor (JIF) — are misused as quick and dirty assessments of scientists’ performance and the quality of their research papers.

“There is a pressing need to improve the ways in which the output of scientific research is evaluated,” DORA says.

Scientists routinely rant that funding agencies and institutions judge them by the impact factor of the journal they publish in — rather than by the work they actually do. The metric was introduced in 1963 to help libraries judge which journals to buy (it measures the number of citations the average paper in a journal has received over the past two years). But it bears little relation to the citations any one article is likely to receive, because only a few articles in a journal receive most of the citations. Focus on the JIF has changed scientists’ incentives, leading them to be rewarded for getting into high-impact publications rather than for doing good science.

“We, the scientific community, are to blame — we created this mess, this perception that if you don’t publish in Cell, Nature or Science, you won’t get a job,” says Stefano Bertuzzi, executive director of the American Society for Cell Biology (ACSB), who coordinated DORA after talks at the ACSB’s annual meeting last year. “The time is right for the scientific community to take control of this issue,” he says. Science and eLife also ran editorials on the subject today.

It has all been said before, of course. Research assessment “rests too heavily on the inflated status of the impact factor”, a Nature editorial noted in 2005; or as structural biologist Stephen Curry of Imperial College London put it in a recent blog post: “I am sick of impact factors and so is science”.

Even the company that creates the impact factor, Thomson Reuters, has issued advice that it does not measure the quality of an individual article in a journal, but rather correlates to the journal’s reputation in its field. (In response to DORA, Thomson Reuters notes that it’s the abuse of the JIF that is the problem, not the metric itself.) Continue reading

US chemist to stand trial over researcher’s death

Chemistry professor Patrick Harran, of the University of California, Los Angeles (UCLA), will face trial on three counts of violating health and safety standards over the death, more than 4 years ago, of 23-year-old research assistant Sheharbano Sangji. A Los Angeles court judge ordered the trial on 26 April.

As far as we know, this is the first time a scientist has gone to trial over an accident in a US academic laboratory. When Harran was charged in 2011, Jim Kaufman, president of the Laboratory Safety Institute in Natick, Massachusetts, said that the legal action was “a game-changer. It will significantly affect how people think about their responsibilities now that it’s clear there’s the possibility of going to jail”.

On 29 December 2008, Sangji was using a syringe to draw the reactive tert-butyllithium from a bottle when the pyrophoric liquid burst into flames, setting her clothes alight. She was not wearing a lab coat and suffered third-degree burns; she died in hospital 18 days later. UCLA has since paid around US$70,000 in fines and toughened its safety policies.

Harran could face 4.5 years in jail if he is convicted of charges that include failing to correct unsafe work conditions and to provide proper chemical safety training. UCLA chancellor Gene Block said that the accident was a tragedy, but was “not a crime. Patrick Harran is a talented and dedicated faculty member, and our support for him is unwavering”.

The governing body of the University of California (the UC regents) had also faced felony charges. But those were dropped last July in a plea agreement, whereby the UC regents set up a $500,000 scholarship in Sangji’s name, accepted responsibility for laboratory conditions at the time of her death and boosted lab-safety training.

A date for Harran’s trial hasn’t yet been set. Chemical & Engineering News has covered the case extensively, as has the Los Angeles Times.

Europe to ban pesticides in effort to protect bees

No one is sure what is causing honeybee colonies to die off around the world, but pesticides called neonicotinoids may be part of the problem. Today, Europe’s health commissioner Tonio Borg said the European Commission would go ahead with a continent-wide plan to severely restrict three of the most commonly-used pesticides in an effort to protect bee health.

The debate over these pesticides has been fierce. (See ‘Europe debates risk to bees’, Nature, 496, 408 (2013)). In use since the late 1990s, they are applied to seeds such as maize and soya beans to protect them from insects – but a growing body of research suggests that bees exposed to the pesticides in nectar and pollen might also be harmed. Much of this research has been conducted in laboratories, with pesticide-manufacturers pitted against conservation groups in arguments over the studies’ significance in the real world.

In January, the European Food Safety Authority in Parma, Italy, Europe’s food-chain risk-assessment body, concluded that three neonicotinoids, clothianidin, imidacloprid and thiamethoxam, should not be used in crops where they might attract bees. The European Commission then proposed two years of restrictions, although not an outright ban: there are some exceptions, such as for crops in greenhouses, or in open-air fields after flowering.

European member states in March didn’t reach the necessary support for the plans (more voted for than against, but the European system requires a ‘qualified majority‘ – about 74% of votes which are themselves weighted by member state). An appeals committee also reached an impasse today, with 15 member states voting for, 8 against (including the United Kingdom), and 4 abstentions. Under European rules, that muddle means the European Commission can choose to go ahead with its proposal.

“I pledge to do my utmost to ensure that our bees, which are so vital to our ecosystem and contribute over €22 billion annually to European agriculture, are protected,” said Borg. The restrictions would apply from 1 December.

The ban goes against the views of the United Kingdom’s new chief scientific adviser, Mark Walport, who last week wrote in the Financial Times that a “moratorium could be harmful to the continent’s crop production, farming communities and consumers”.

Environmental groups were delighted with the decision, pronouncing it a victory for the precautionary principle. Some researchers said it wasn’t clear that a two-year ban would be sufficient to show whether or not the pesticides were harming the bees (particularly if other suspects for colony collapses, such as the parasitic mite Varroa destructor and the parasitic fungus Nosema apis, are also involved).

But others said the ban didn’t go far enough. The UK’s Science Media Centre has collected varying reactions from bee scientists: among them, David Goulson, a bee researcher at the University of Sussex, noted that the pesticides would continue to be used on some crops, such as wheat, and called for a wider reduction of pesticide use.

Europe’s politicians leave carbon market in coma

Politicians in Europe’s parliament today narrowly rejected a plan to revive prices on the region’s carbon market — the world’s largest — which have collapsed in the recession. The decision condemns the carbon-trading scheme to irrelevancy, at least in its current 2013–20 incarnation, analysts said. Prices will stay far too low to spur the investment in low-carbon energy that was one of the scheme’s key goals when it was launched in 2005.

In the market, polluters from 27 member states buy and sell permits to emit carbon dioxide under an overall emissions cap. If permits get too expensive — say, upwards of €30 (US$40) per tonne — industry would find it worthwhile to generate energy without emitting carbon dioxide. But the financial recession led to a slump in industrial activity, and the region’s emissions are now far below the cap set by politicians.

This has left the market awash in unneeded allowances. Permit prices fell below €4 in January. Thomson Reuters Point Carbon, a consultancy firm in Oslo, estimates an oversupply of about 2 billion tonnes of carbon allowances from 2013 to 2020 (equivalent to one year’s emissions from all the polluters in the scheme).

On the plus side, the recession means Europe will easily meet its emissions target (a 20% reduction in greenhouse-gas levels by 2020). But the resulting low market prices mean the region has little incentive to invest in technology that would keep it on a low-carbon path through to 2050.

One casualty is carbon capture and storage technology, which was supposed to benefit specifically from sales of market permits.

So the European Commission had suggested taking 900 million tonnes of allowances out of the scheme up to 2015, effectively tightening the emissions cap and raising prices. The allowances would be re-injected into the market sometime before 2020, effectively ‘back-loading’ the permits. But in a 334-to-315 vote, members of the European Parliament narrowly rejected that idea, worrying about rising energy costs.

As a result, the market is likely to limp along at current levels — of about €3–4 per tonne of carbon dioxide — until 2020, the end of the current trading period, says Stig Schjolset, an analyst at Thomson Reuters Point Carbon. In theory, the idea is not entirely kaput: the parliament’s environment committee will look again at the scheme. But political will is lacking: “For all practical purposes, it’s politically dead”, says Schjolset.

Continue reading

UK budget leaves science funding falling slowly

If UK researchers thought they would catch a sneak glimpse of June’s hotly anticipated multi-year spending plan for science in today’s 2013 budget, they were disappointed. In his budget speech, Chancellor George Osborne gave a tantalizing hint that “existing protections” would apply for future spending — meaning that research budgets may be left undamaged — but made no specific mention of science.

The only announcement that might affect cash for research this year was indirect: a 1% cut from the spends of many ministerial departments, including that responsible for science, the Department for Business, Innovation and Skills. This will not directly affect research grant money, but departments might make savings by cutting their own research spending.

And so the budget leaves British science funding largely where it was: that is to say, eroding slowly up to 2014–15. To summarize the events of the past four years: in the 2010 four-year spending plan, although it promised to protect science grant money, the government slashed funding for research infrastructure. Since then, it has been slowly re-injecting the lost cash, in successive annual budgets announcing money for areas such as graphene, synthetic biology, energy storage and advanced materials.

Osborne seemed to have rediscovered a love for science as an economic driver — and he expressed that love by giving back some of what had been cut. (But not quite all — planned spending for grants and associated infrastructure in 2014–15 is still some 7% lower than in 2010–11, and that does not include further losses from inflation, according to analysis from the London-based Campaign for Science and Engineering.)

Continue reading

AstraZeneca continues research cuts

In a fourth series of cuts in six years, UK-based drug firm AstraZeneca said yesterday that it would cut 1,600 staff – 1,300 of whom are researchers, about 10% of the company’s current research capacity – in a restructuring plan that would see scientists concentrated in three major research sites: Cambridge, UK; Gaithersburg, Maryland, and Mölndal, Sweden.

As a rough estimate, that suggests that the firm has now announced cuts that slash its research capacity by 25% since 2006. (According to the latest investor presentation in February (see slide 127), and adding in yesterday’s announcement, the company will have cut some 8,000 research jobs, but regained 4,000 through re-investments including the acquisition of MedImmune; in turn, that suggests its research strength lay at around 16,000 scientists in 2006, and will drop to below 12,000 scientists in future).

AstraZeneca will do some some investing, putting in $500 million for a new facility in Cambridge, UK. But its $1.4 billion restructuring includes closing down all research at Alderley Park in Cheshire, UK. Last year, it shut down research sites in Södertälje, Sweden, and Montreal, Canada.

In January, the company said last year’s revenue was down 15% to $28 billion. Like much of the pharma industry, AstraZeneca is falling down the patent cliff. It is losing revenue as its best-selling drugs face generic competitors, including antipsychotic drug Seroquel, and in the US, ulcer treatment Nexium by the end of 2014 and cholesterol treatment Crestor by 2016.

India fails to deliver on promises to boost science budget

Posted on behalf of K.S. Jayaraman.

For the second year in a row, scientists in India feel let down by a government that promises large funding boosts for research — but isn’t delivering the goods in its budget.

In January, prime minister Manmohan Singh said the country should aim to double its research expenditure by 2017, to reach 2% of its gross domestic product. Under a new policy on science, technology and innovation, India was supposed to be increasing its number of scientists by 66% by 2017, and enhance private-sector participation in research; the spending targets were also proposed in a five-year plan released in December 2012.

But the government’s proposals in India’s 2013–14 budget, released last week, indicate that it is actually trying to cut research spending. Nine research departments* share some US$6.9 billion, a mere 4% more than budgeted for 2012–13, and below the rate of inflation. (The exact size of India’s government research spend depends on which ministries are included in the calculation.)

In fact, the previous year’s budget for those departments was subsequently revised downwards by some 30%, so that some reports (such as that of SciDev.Net) say the new budget — compared to last year’s revised figures — represent a substantial boost. Other reports, such as Science Insider‘s, call the budget lacklustre.

Last year’s budget — even before the revisions — was itself disappointing, as the country is reining in spending across the board.

“The resources allocated to science and technology are a matter of concern,” says Ajay Sood, a physicist at the Indian Institute of Science in Bangalore and a former president of the Indian Academy of Science. “This resource crunch has come at a time when the science scene in India was beginning to look good.”

C.N.R. Rao, who heads the prime minister’s science advisory council, says that he is glad that science at least escaped big cuts. “I am told that the promised big spending will start from 2014,” he said. “I hope so. But next year is the election year and I have no idea what will happen [to the promises made by this government].”


*Budget documents used from departments of atomic energy, health research, agricultural research, Earth sciences, space, defence research and the Ministry of Science and Technology’s departments of biotechnology, science and industrial research and science and technology.

Nature Publishing Group buys into open-access publisher

One of the fastest-growing open-access publishers, Frontiers, has been snapped up by Nature Publishing Group (NPG, which publishes this blog as part of Nature.com), the company announced today.

Frontiers was co-founded in 2007 by its current chief executive Kamila Markram, who is a neuroscientist studying autism at the Swiss Federal Institute of Lausanne. (The company itself, a private firm, is headquartered at a technology park in Lausanne. For more on the firm, see Nature‘s 2010 article ‘Publisher seeks patent’.)

Last year, Frontiers published 5,000 articles in 14 journals, to become the world’s fifth-largest open-access publisher. (NPG itself published just more than 2,000 open-access articles in 2012.) But Frontiers’ unique selling point is its concept as a community-driven networking platform, says Markram.

Academic editors can commission special topics around particular subjects; apart from regular CC-BY open-access articles at fees of between €770 (US$1,006) and €1,600 ($2,090), authors contribute (at no publishing charge) news about seminars, conferences and other events, as well as blogs and other content.

Continue reading

White House announces new US open-access policy

In a long-awaited leap forward for open access, the US government said today that publications from taxpayer-funded research should be made free to read after a year’s delay — expanding a policy that has, until now, applied only to biomedical science.

In a memo, John Holdren, the director of the White House office of science and technology policy (OSTP), told federal agencies to prepare plans to make their research results free to read within 12 months after publication.

“The Obama Administration is committed to the proposition that citizens deserve easy access to the results of scientific research their tax dollars have paid for,” the memo says. The OSTP also tells agencies to maximize public access to non-classified scientific data from research they fund.

The policy applies to all federal agencies that spend more than US$100 million on research and development, and is likely to double the number of articles made public each year. The US National Institutes of Health (NIH) has since 2008 required research to be publicly accessible after 12 months. “This new policy call does not insist that every agency copy the NIH approach exactly, [but] it does ensure that similar policies will appear across government,” Holdren wrote today in a separate response to a petition that was launched in May 2012, urging the president to require free access to scientific journal articles from publicly funded research. (That has gathered some 64,000 signatures.)

The policy has been a long time in preparation, both at the OSTP and at federal agencies. The OSTP had asked for public views on the subject twice already, in 2009 and again in 2011. It had been charged with improving public access to research under a re-authorization of the America COMPETES Act, in December 2010. Meanwhile, both the National Science Foundation (NSF) and the Department of Energy (DOE) have been talking to researchers and publishers over the last 18 months about new public-access and data-management policies, says Fred Dylla, the executive director of the American Institute of Physics, a publisher based in College Park, Maryland.

Federal agencies have been told to provide the OSTP with their draft policies in six months’ time.  They are allowed some flexibility, with the 12-month embargo only a “guideline” — suggesting that different embargo periods might apply in different disciplines. That is a key concern for publishers, who also want to know whether federal agencies will set up repositories of their funded work, rather like the NIH’s PubMed Central (PMC). Martin Frank, executive director at the American Physiological Society, argues that PMC has pulled viewers away from accessing articles on publisher sites, for example.

The White House statement comes a week after a bill, FASTR (‘Fair access to science and technology research’), which would require public access to papers just six months after publication, was introduced into the US Congress.

Whatever the fate of that legislation, it is now clear that US public-access policy is taking a different direction from that in the United Kingdom, where government-funded science agencies want authors to pay publishers up front to make their work free to read immediately. This immediate open-access policy involves extra money taken from science budgets to pay publishers. NSF director Subra Suresh explained to Nature that he could not justify taking money out of basic research to pay for open access at a time when demand for the agency’s funding was high.

With both the United States and Europe supporting delayed access to publications, the UK government looks increasingly isolated in its preference for immediate open access. That policy is due to come in from 1 April, but the details are not yet clear. Communication around the policy was yesterday criticized as “unacceptable” by a House of Lords inquiry.